What is the goal of the nationwide MDR/RR-TB cohort study conducted as part of No1Lost?

The primary objective of the study is to conduct a comprehensive scientific analysis of treatment outcomes for patients with multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB) in Germany. In particular, the study aims to investigate the causes of treatment discontinuation. The detailed data collection at 20 hospitals covers demographic, clinical, microbiological, and, in particular, social factors. In addition, the prospective study aims to gain insights into the efficacy of new combination therapies and the care structures for MDR/RR-TB in Germany in order to improve treatment in the long term. The study is being conducted as part of the No1Lost project and will initially recruit participants through the second quarter of 2027. The study receives research funding from the Federal Ministry of Health (BMG).